Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease. Issue 12 (4th February 2021)

• Record Type: Journal Article
• Authors: Mahmmod, Shaden; Schultheiss, Johannes P D; van Bodegraven, Ad A; Dijkstra, Gerard; Gilissen, Lennard P L; Hoentjen, Frank; Lutgens, Maurice W M D; Mahmmod, Nofel; van der Meulen–de Jong, Andrea E; Smits, Lisa J T; Tan, Adriaan C I T L; Oldenburg, Bas; Fidder, Herma H
• Is Part Of: Inflammatory bowel diseases. Volume 27:Issue 12(2021)
• Page Start: 1954
• Page End: 1962
• Publication Date: 2021-02-04
• Subjects: inflammatory bowel disease -- Crohn disease -- ulcerative colitis -- biologic therapy -- infliximab -- biosimilars -- anti-TNF-alpha; Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izaa364
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract: Background: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator. Here we assess the prevalence of reverse switching, including its indication and outcomes. Methods: In this retrospective multicenter cohort study, data on patients with IBD from 9 hospitals in the Netherlands were collected. All adult patients with IBD were included if they previously had been switched from originator infliximab to the biosimilar CT-P13 and had a follow-up time of at least 52 weeks after the initial switch. The reasons for reverse switching were categorized into worsening gastrointestinal symptoms, adverse effects, or loss of response to CT-P13. Drug persistence was analyzed through survival analyses. Results: A total of 758 patients with IBD were identified. Reverse switching was observed in 75 patients (9.9%). Patients with reverse switching were predominantly female (70.7%). Gastrointestinal symptoms (25.5%) and dermatological symptoms (21.8%) were the most commonly reported reasons for reverse switching. In 9 patients (12.0%), loss of response to CT-P13 was the reason for reverse switching. Improvement of reported symptoms was seen in 73.3% of patients after reverse switching and 7 out of 9 patients (77.8%) with loss of response regained response. Infliximab persistence was equal between patients who were reverse-switched and those who were maintained on CT-P13. Conclusions: Reverse switching occurred in 9.9% of patients, predominantly for biosimilar-attributed adverse effects. Switching back to originator infliximab seems effective in patients who experience adverse effects, worsening gastrointestinal symptoms, or loss of response after switching from originator infliximab to CT-P13.